Document is current
Any future updates will be listed below
-
Authors
Xue, Xuemin
Guo, Lei
Guo, Changyuan
Li, Lin
Yang, Lin
Wang, Xin
Rao, Wei
Yuan, Pei
Mu, Jiali
Li, Jiangtao
Wang, Bingning
Zhou, Quan
Yang, Wentao
Liu, Yueping
Xue, Weicheng
Jia, Rujing
Yang, Wenjing
Ying, Jianming
-
Funding
Funding for this research was provided by:
National Anti-Tumor Drug Surveillance System of National Cancer Center (DSS-YSF2022-08)
- License Information
-
More Information
Article History
Received: 22 May 2023
Accepted: 20 December 2023
First Online: 2 January 2024
Declarations
:
: This is a retrospective study which did not affect the patient’s therapy, and no patient privacy information is involved. Therefore, this study was approved by the ethical approval from the Independent Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences, National GCP Center for Anticancer Drugs (22/499–3701), with waiver of informed consent. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: The authors declare no competing interests.
